2-(4-氟苯基)-5-(三氟甲基)-1H-咪唑 | 33469-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-氟苯基)-5-(三氟甲基)-1H-咪唑
• 英文名称: 2-(4-fluorophenyl)-5-(trifluoromethyl)-1H-imidazole
• 英文别名: 2-(4-fluoro-phenyl)-4-trifluoromethyl-1(3)H-imidazole
• CAS: 33469-12-4
• 化学式: C₁₀H₆F₄N₂
• 分子量: 230.165
• InChiKey: JWQVMMHWTAFPQR-UHFFFAOYSA-N

物化性质

• 熔点：
  203-205 °C
• 沸点：
  330.2±42.0 °C(Predicted)
• 密度：
  1.403±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-氟苯基)-5-(三氟甲基)-1H-咪唑 在 氯化亚砜 、 水 、 sodium hydroxide 作用下， 反应 19.0h， 生成 methyl 2-(4-fluorophenyl)-1H-imidazole-5-carboxylate
  参考文献：
  名称：

  PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

  摘要：

  该发明涉及对USP7抑制剂的抑制剂，用于治疗癌症、神经退行性疾病、免疫性疾病、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病以及细菌感染和疾病，其化学式为：其中R1、R2、R3、R4、R5、R5'、R6、X1、X2、m和n如本文所述。

  公开号：

  US20160185786A1
• 作为产物：
  描述：

  对氟苯甲醛 、 1,1-二溴-3,3,3-三氟丙酮 在 sodium acetate 、 ammonium hydroxide 作用下， 以 水 、 甲醇 为溶剂， 反应 4.5h， 以45%的产率得到2-(4-氟苯基)-5-(三氟甲基)-1H-咪唑
  参考文献：
  名称：

  PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

  摘要：

  该发明涉及对USP7抑制剂的抑制剂，用于治疗癌症、神经退行性疾病、免疫性疾病、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病以及细菌感染和疾病，其化学式为：其中R1、R2、R3、R4、R5、R5'、R6、X1、X2、m和n如本文所述。

  公开号：

  US20160185786A1

文献信息

• Fluorinated imidazoles as 19F probes for biomimetic studies of heme a3 — Cub site in cytochrome c oxidase
  作者：James P. Collman、Roman Boulatov、Christopher J. Sunderland、Min Zhong

  DOI：10.1016/s0022-1139(00)00328-6

  日期：2000.12

  A series of 4,5-imidazole carboxylic acids bearing fluorinated substituents is synthesized from simple commercially available fluorinated substrates utilizing several different approaches to modify the imidazole core. These imidazole derivatives are specifically designed to be sensitive probes for physicochemical studies of processes in the coordination environments of metals employing 19F-NMR techniques

  使用几种不同的方法修饰咪唑核心，从简单的可商购的氟化底物合成一系列带有氟化取代基的4,5-咪唑羧酸。这些咪唑衍生物经过专门设计，是用于使用19 F-NMR技术对金属配位环境中的过程进行物理化学研究的灵敏探针，特别是在我们正在进行的对咪唑衍生的卟啉的仿生研究中。
• Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
  申请人：Forma Therapeutics, Inc.

  公开号：US10000495B2

  公开（公告）日：2018-06-19

  The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.

  本发明涉及可用于治疗癌症、神经退行性疾病、免疫性疾病、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病以及细菌感染和疾病的USP7抑制剂，其具有如下式子： 其中 R1、R2、R3、R4、R5、R5′、R6、X1、X2、m 和 n 在本文中描述。
• Synthesis, Structure, and Neuroprotective Properties of Novel Imidazolyl Nitrones
  作者：Alain Dhainaut、André Tizot、Eric Raimbaud、Brian Lockhart、Pierre Lestage、Solo Goldstein

  DOI：10.1021/jm991154w

  日期：2000.6.1

  A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivity imparts to the nitrone superior neuroprotective properties in vivo and in parallel reduced side effects and toxicity. Thus compound 6a (a 2-phenylimidazolyl nitrone) administered intraperitoneally protects (80%) mice from lethality induced by an intracerebroventricular administration of tert-butyl hydroperoxide (t-BHP) an oxidant capable of inducing neurodegenerative processes. Administration of the archetypal nitrone phenyl-tert-butyl nitrone (PBN) at an equimolar dose also affords some protection (60%) in this test. However, this activity is accompanied by hypothermia, whereas no such effect is apparent for 6a. Moreover, previously prepared nonsubstituted or alkyl-substituted imidazolyl nitrones were shown to be extremely toxic to rats in contrast to the compounds prepared in this study. The observed activities in vivo correlate well with the calculated partition coefficients (ClogP) and HOMO energy level.
• PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Forma Therapeutics, Inc.

  公开号：EP3240790A1

  公开（公告）日：2017-11-08
• [EN] PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA PYRROLOTRIAZINONE ET DE L'IMIDAZOTRIAZINONE EN TANT QU'INHIBITEURS DE LA PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE N° 7 (USP7) POUR LE TRAITEMENT D'UN CANCER
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2016109480A1

  公开（公告）日：2016-07-07

  The invention relates to pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one and imidazo[5,1-f][1,2,4]triazin-4(3H)-one derivatives as inhibitors of the ubiquitin-specific protease 7 (USP7) useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula (I) where Rl, R2, R3, R4, Rs, Rs', R6, Xl, X2, m, and n are described herein.